Clovis Oncology has a number of regulatory catalysts that can drive share price higher.
Scientific Advisory issued a positive opinion on approval in Europe to the CHMP.
Strong data from ARIEL3 favors approval in April FDA PDUFA.
Share price weakness is a good entry point ahead of upcoming catalysts.
Clovis Oncology, Inc. (CLVS) is a biopharmaceutical company with lead drug Rubraca (Rucaparib) an anti-cancer drug in a new class of PARP inhibitors. The company share price has previously been above $100 with recent 52 week high of $99.45. The decline can be attributed to slow uptake of PARP inhibitors in general and the increase in competition. Despite the pressured stock price the company is positioned to grow their market share and achieve a higher stock price in the near term due to some important catalysts. This is an excellent opportunity to acquire shares ahead of the news.
Rubraca an oral small molecule works as an inhibitor of PARP1, PARP2, and PARP3. This lead drug is being developed in a number of indications for advanced ovarian cancer, and metastasized castration resistant prostate cancer. Other major programs are sponsored with Bristol-Myers Squibb (BMY) for specific types of breast cancer.